News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
GW Pharmaceuticals Begins Second Pivotal Phase III Trial Of MS Drug Sativex
August 9, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
GW Pharmaceuticals PLC said it has begun a second pivotal Phase III trial of Sativex as a treatment for pain associated with multiple sclerosis.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 3
Europe
MORE ON THIS TOPIC
Women’s health
Kailera, Hengrui’s GLP-1/GIP candidate delivers weight, menstrual benefits to women with PMOS
October 2, 2026
·
2 min read
·
Tristan Manalac
Drug Development
Merck’s antibody impresses with ‘highly competitive’ data in chronic skin disease
October 1, 2026
·
2 min read
·
Tristan Manalac
Idiopathic pulmonary fibrosis
BMS reports liver injury events in lung disease program, with key readout near
October 1, 2026
·
3 min read
·
Annalee Armstrong
Obesity
Zealand dips as Boehringer Ingelheim-partnered weight loss drug fails to impress—again
October 1, 2026
·
2 min read
·
Heather McKenzie
